about
Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel diseaseSystematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitisSevere adalimumab-induced thrombocytopenia in a patient with Crohn's disease.Clinical patterns and outcomes of ischaemic colitis: results of the Working Group for the Study of Ischaemic Colitis in Spain (CIE study).Accuracy of computed tomographic colonography for the detection of polyps and colorectal tumors: a systematic review and meta-analysis.Tuberculosis in Anti-Tumour Necrosis Factor-treated Inflammatory Bowel Disease Patients After the Implementation of Preventive Measures: Compliance With Recommendations and Safety of Retreatment.Effectiveness of infliximab after adalimumab failure in Crohn's diseaseExtracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry.High-dose intravenous treatment in iron deficiency anaemia in inflammatory bowel disease: early efficacy and impact on quality of lifeReview article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.Transplacental transfer of immunosuppressants and biologics used for the treatment of inflammatory bowel disease.Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease.Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease.Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study.Systematic review: antibodies and anti-TNF-α levels in inflammatory bowel disease.Dysplasia and colorectal cancer in a patient with ulcerative colitis and primary sclerosing cholangitis: a case report and a short review of the literature.Vaccination strategies in patients with IBD.Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease.Angiopoietins in inflammation and their implication in the development of inflammatory bowel disease. A review.Health care costs of complex perianal fistula in Crohn's disease.Systematic review with meta-analysis: inflammatory bowel disease in the elderly.How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease?Measurement of anti-TNF agents and anti-drug antibodies serum levels in patients with inflammatory bowel disease.Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it?Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy.Ratio of Circulating Estrogen Receptors Beta and Alpha (ERβ/ERα) Indicates Endoscopic Activity in Patients with Crohn's Disease.Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study.The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.Maintenance therapy options for ulcerative colitis.Treatment of inflammatory bowel disease: what's new in Digestive Disease Week 2016.Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients.Utility of measuring serum concentrations of anti-TNF agents and anti-drug antibodies in inflammatory bowel disease.Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience.Endoscopist characteristics that influence the quality of colonoscopy.Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus-A Multicenter Retrospective Study.Angiogenesis: from chronic liver inflammation to hepatocellular carcinoma.Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis.Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study.[Natural history, complications, safety and pregnancy in inflammatory bowel disease].
P50
Q26777330-9E879A0C-C1E4-41CC-ACA4-8A8A310D4DFAQ27011853-FE74707C-6045-45E5-A9ED-968A01A137CDQ33400929-297FD9CC-6F79-476F-85D8-9B869D38E8D8Q34624525-CFB967CF-1A10-4D63-A1FC-EDB3EE4B332BQ34658454-35D54F90-808A-463A-B576-90836C21BF12Q35902266-97FCCF3C-DB02-4E98-A0A4-E4D93808B2F8Q36310429-4AE84D94-4951-44F7-9BCB-C65673C59A27Q36378458-94BC67A8-4DD7-4F87-B820-0D402834AAEFQ37032277-7F41B889-D8B5-422E-894F-3CC5FD9164AEQ37276117-1D350595-C564-45AA-9FF3-4E5791E89EB6Q37845884-C7703AB3-08F5-4547-9209-91429E4874BEQ37854550-57120A02-06D5-4516-A915-652C2ED0C72AQ37880179-BCF20B51-122C-4EAF-8DC2-59E42D3637D4Q37964767-8E31EEC6-083B-4C60-A477-7385D89FE573Q37996426-F2595871-3312-478C-8DDF-1F1217D41CF8Q38007081-D1515C13-D7EF-44E5-840A-9877EBDAFADBQ38082568-2482155E-5FD5-4B86-8DB6-631422355662Q38113455-37D288F6-3018-4D56-81D7-4E976D2491AAQ38122003-4DA4140F-F9E6-4EDB-BB3D-BD6B56E9C459Q38136533-FEDF99DC-61AF-436B-A2CC-D49D2D3380B4Q38176953-5191B8C8-768C-4DE1-8435-C6CCB3B2D935Q38253145-76AF4A6E-075D-4E1E-B54A-4DC1C2A567A9Q38265420-0411938F-E651-42FF-90C4-A9D4E3B26924Q38337716-4A04605A-6784-4B33-A17B-CE216F3915F2Q38344622-E0604DB4-EE70-4641-88D7-20282EECEB94Q38527999-333299BD-E2BC-4AB2-B75D-8900B212AFFEQ38617399-E243DA46-050A-4E9B-A010-C58CC60DD134Q38694769-48E633E5-638D-4796-910A-B33E725C1D73Q38784697-EED86DAF-76EA-46F2-9175-03873119228BQ38848140-38A81668-3513-41F4-9685-3E72F5510F71Q39152409-50740399-7161-4F9D-A749-AD512DFDF358Q39306418-BD397902-621D-4936-B13F-21916593B9E7Q39760177-9567B807-524E-4A8D-89C0-F91601863ED7Q39989585-2A54B7B0-C636-4E25-8BA6-E9BE3E6AA312Q40023997-6A40BF4E-FE1E-4FC3-9C69-6578D43195A2Q40181878-DCFB030A-BB47-4ACC-B11B-FC1DB30B0AF0Q40818347-4AAB0338-EDD0-4B79-84B0-EA7F66F6C366Q40868226-FF57F580-3C34-4DBC-90D8-0604F9A02ADDQ40876904-FC8A9B1A-3076-451A-8AC6-6EEA5A6461BAQ40928970-A6580C3D-62AB-46A7-8227-7E3E35BC50B8
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
María Chaparro
@ast
María Chaparro
@en
María Chaparro
@es
María Chaparro
@nl
María Chaparro
@sl
type
label
María Chaparro
@ast
María Chaparro
@en
María Chaparro
@es
María Chaparro
@nl
María Chaparro
@sl
prefLabel
María Chaparro
@ast
María Chaparro
@en
María Chaparro
@es
María Chaparro
@nl
María Chaparro
@sl
P106
P1153
24436876600
P21
P31
P496
0000-0002-9275-4242